EXTRAITS CONTENANT UN LIGNANE DE MAGNOLIAE FLOS ET UTILISATION ASSOCIEE DANS LE TRAITEMENT ET LA PREVENTION DE MALADIE PULMONAIRE OBSTRUCTIVE CHRONIQUE (MPOC)
The present invention relates to a pharmaceutical composition for preventing or treating chronic obstructive lung disease, the composition containing, as an active ingredient, any one of a Magnoliae flos extract, a fraction thereof obtained by fractionation using an organic solvent, an active fraction, or a compound separated therefrom. It was verified that the Magnoliae flos extract, the fraction thereof obtained by fractionation using an organic solvent, the active fraction, or the compound separated therefrom, can be used to treat chronic obstructive lung disease by inhibiting the TNF-a-induced MUC5AC expression or promoter activity in human lung cancer mucosal cells (H292), suppressing the number of inflammatory cells in the bronchoalveolar lavage fluid of a chronic obstructive lung disease mouse model, inhibiting the generation of reactive oxygen species, and reducing cytokines. Therefore, the Magnoliae flos extract, the fraction thereof obtained by fractionation using an organic solvent, the active fraction, or the compound separated therefrom, of the present invention, can be favorably used as a pharmaceutical composition for preventing or treating chronic obstructive lung disease.
